Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Infliximab biosimilar - Celltrion

Next Previous
Drug Profile

Infliximab biosimilar - Celltrion

Alternative Names: Anti-TNF alpha Mab; Anti-TNF alpha monoclonal antibody; CT-P13; CT-P13 IV; CT-P13 SC; Inflectra; Infliximab biosimilar - Hospira; Remsima; RemsimaSC; ZYMFENTRA

Latest Information Update: 28 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celltrion
  • Developer Alvogen; Celltrion; Hospira; Kern Pharma; Nippon Kayaku; Orion
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ankylosing spondylitis; Crohn's disease; Inflammatory bowel diseases; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis

Most Recent Events

  • 23 Feb 2024 Updated efficacy and adverse events data from the phase III LIBERTY-UC trial in Ulcerative colitis released by Celltrion
  • 23 Feb 2024 Updated efficacy and adverse events data from the phase III LIBERTY-CD trial in Crohn's disease released by Celltrion
  • 19 Feb 2024 Health Canada approves infliximab biosimilar for Crohn's disease and Ulcerative colitis in Canada
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top